The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages. The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and [...]
This is an updated Joint BMS, IMS, EMAS, RCOG and AMS Position Statement on HRT and breast cancer risk and includes a summary of the evidence on dydrogesterone. We are aware that the statement is likely to be used by healthcare professionals to guide clinical practice and we believe this additional information would be of [...]
A joint statement has been issued by the British Menopause Society, the International Menopause Society, the European Menopause and Andropause Society, the Royal College of Obstetricians and Gynaecologists and the Australasian Menopause Society on menopausal hormone therapy (MHT) and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.
A joint statement has been issued by the British Menopause Society, the Royal College of Obstetricians and Gynaecologists, the Royal College of General Practitioners, the Faculty of Sexual and Reproductive Healthcare, the Faculty of Occupational Medicine and the Faculty of Public Health in response to the BMA report ‘Challenging the culture on menopause for doctors’.
The RCOG and BMS issue a joint statement on the Women’s Health Initiative’s (WHI) study on HRT and breast cancer incidence and mortality.
Menopausal hot flushes and sweats affect around 80% of women, can cause significant distress and can last for many years. Hormone Replacement Therapy is recommended as first line treatment, but is not appropriate nor desired by all women with symptoms. This is especially relevant to women who have had hormone dependant cancer. Non hormonal treatments [...]
It has been recognised for many years that more women than men are affected by Alzheimer’s Dementia (AD). Female hormones have been thought to play a role and new information adds more evidence to the debate. A recently published study investigated the differences in brain biomarkers of AD in men and women. (A biomarker is [...]
The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages.
Please see a joint framework statement from the BMS, RCOG, RCGP and FSRH regarding the restoration of menopause services in response to COVID-19.
A Primary Care Women’s Health Forum Webinar on how to manage HRT provision without face to face consultations during COVID-19 healthcare restrictions is taking place on Thursday 4 June 2020 at 7pm
